Literature DB >> 10365802

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.

O Reichard1, H Glaumann, A Frydén, G Norkrans, R Wejstål, O Weiland.   

Abstract

BACKGROUND/AIMS: This study aimed to determine the long-term outcome of hepatitis C virus (HCV)-infected patients who respond to interferon treatment with clearance of serum HCV RNA.
METHODS: We performed a long-term biochemical, virological, and histological follow-up of all sustained virological responders, defined as those who became HCV RNA negative at follow-up 6 months after the end of treatment, from 3 controlled interferon trials performed in Sweden between 1988 and 1994.
RESULTS: At biochemical and virological long-term follow-up performed in 26 sustained virological responders 3.5-8.8 years (mean +/- SD, 5.4+/-1.6 years) after the end of IFN therapy, 22 patients (85%) had normal serum ALT levels, and 24 patients (92%) were HCV RNA negative in serum. Liver biopsies performed in 23 patients 2.1-8.7 years (mean +/- SD, 5.0+/-1.8 years) after end of treatment showed no or minimal inflammation, whereas mild and probably irreversible fibrosis was seen in a few patients.
CONCLUSION: In this well-defined material of sustained responders to IFN therapy, the long-term prognosis was excellent. Nearly all had a durable response, not only biochemically and virologically, but more importantly also histologically with normalisation or near normalisation of previous histological lesions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10365802     DOI: 10.1016/s0168-8278(99)80129-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  22 in total

1.  Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.

Authors:  María Trapero-Marugán; Jorge Mendoza; María Chaparro; Leticia González-Moreno; José Andrés Moreno-Monteagudo; María Jesús Borque; Ricardo Moreno-Otero
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

Review 2.  Treatment of hepatitis C. The 2002 French consensus.

Authors:  D Dhumeaux; P Marcellin; E Lerebours
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

3.  Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment.

Authors:  Disaya Chavalitdhamrong; Tawesak Tanwandee
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

Review 4.  Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.

Authors:  John B Wong
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.

Authors:  Sarah L George; Bruce R Bacon; Elizabeth M Brunt; Kusal L Mihindukulasuriya; Joyce Hoffmann; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

6.  Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.

Authors:  Atsushi Tanaka; Satoko Uegaki; Hiroko Kurihara; Kiyoshi Aida; Masaki Mikami; Ikuo Nagashima; Junji Shiga; Hajime Takikawa
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

7.  Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.

Authors:  Chihiro Morishima; Timothy R Morgan; James E Everhart; Elizabeth C Wright; Minjun C Apodaca; David R Gretch; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; William M Lee; Anna S F Lok; Jules L Dienstag; Marc G Ghany; Teresa M Curto
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

8.  Development of hepatocellular carcinoma in patients with chronic hepatitis C more than 10 years after sustained virological response to interferon therapy.

Authors:  Keiichiro Nojiri; Kazushi Sugimoto; Katsuya Shiraki; Satoko Kusagawa; Junichiro Tanaka; Tetsuya Beppu; Norihiko Yamamoto; Yoshiyuki Takei; Akira Hashimoto; Atsuya Shimizu; Shigeru Omori; Masahiko Tameda; Koujiro Takase
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

9.  Sustained virological response: a milestone in the treatment of chronic hepatitis C.

Authors:  Filomena Morisco; Rocco Granata; Tommaso Stroffolini; Maria Guarino; Laura Donnarumma; Laura Gaeta; Ilaria Loperto; Ivan Gentile; Francesco Auriemma; Nicola Caporaso
Journal:  World J Gastroenterol       Date:  2013-05-14       Impact factor: 5.742

10.  Persistence of hepatitis C virus in peripheral blood mononuclear cells of sustained viral responders to pegylated interferon and ribavirin therapy.

Authors:  Juan F Gallegos-Orozco; Jorge Rakela; Marianne J Rosati; Hugo E Vargas; Vijayan Balan
Journal:  Dig Dis Sci       Date:  2008-07-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.